Amryt Pharma pleased with progress, announces new in-licence agreement
Amryt Pharma
143.00p
16:55 10/01/22
-11.73%
-19.00p
Rare and orphan disease-focussed biopharmaceutical company Amryt Pharma updated the market on its trading on Thursday, and announced that it has concluded terms for an exclusive in-licence agreement for a novel gene therapy platform, offering a “potentially exciting” treatment for patients with epidermolysis bullosa (EB).
Financial Services
14,051.23
16:59 26/04/24
0.59%
81.87
FTSE AIM All-Share
755.28
17:14 26/04/24
n/a
n/a